Notification of major interest in Mediclinic International plc shares
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
(“Mediclinic”, the “Company” or the “Group”)
14 December 2018
Notification of Major Interest in Mediclinic International plc shares
1a. Identity of the issuer or the underlying issuer Mediclinic International plc.
of existing shares to which voting rights are at-
tached:
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights X
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify):
3. Details of person subject to the notification obligation
Name Coronation Asset Management (Pty) Ltd acting as dis-
cretionary investment manager on behalf of managed
portfolios.
City and country of registered office (if applicable) Cape Town, South Africa
4. Full name of shareholder(s) (if different from 3.)
Name N/A
City and country of registered office (if applicable)
5. Date on which the threshold was crossed or 14/12/2018
reached:
6. Date on which issuer notified (DD/MM/YYYY): 14/12/2018
7. Total positions of person(s) subject to the notification obligation
% of voting rights at- % of voting rights Total of both in % Total number of
tached to shares (to- through financial instru- (8.A + 8.B) voting rights of is-
tal of 8. A) ments suer
(total of 8.B 1 + 8.B 2)
Resulting situation 3.98 3.98 737 243 810
on the date on which
threshold was
crossed or reached
Position of previous 4.06 4.06
notification (if
applicable)
8. Notified details of the resulting situation on the date on which the threshold was crossed or
reached
A: Voting rights attached to shares
Class/type of Number of voting rights % of voting rights
shares
ISIN code (if possible) Direct Indirect Direct Indirect
(Art 9 of Directive (Art 10 of Directive (Art 9 of Directive (Art 10 of Directive
2004/109/EC) (DTR5.1) 2004/109/EC) 2004/109/EC) (DTR5.1) 2004/109/EC)
(DTR5.2.1) (DTR5.2.1)
GB00B8HX8Z88 29 324 201 3.98
SUBTOTAL 8. A 29 324 201 3.98
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Type of financial in- Expiration Exercise/ Number of voting rights % of voting rights
strument date Conversion Period that may be acquired if
the instrument is
exercised/converted.
SUBTOTAL 8. B 1
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive
2004/109/EC (DTR5.3.1.1 (b))
Type of financial Expiration Exercise/ Physical or Number of % of voting rights
instrument date Conversion Pe- cash voting rights
riod settlement
SUBTOTAL
8.B.2
9. Information in relation to the person subject to the notification obligation (please mark the
applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not
control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer
Full chain of controlled undertakings through which the voting rights and/or the X
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity
(please add additional rows as necessary)
Name % of voting rights % of voting rights Total of both if it
if it equals or is through financial equals or is higher
higher than the instruments if it than the notifiable
notifiable thresh- equals or is higher threshold
old than the notifiable
threshold
Coronation Fund Managers Ltd
Coronation Investment Management
SA (Pty) Ltd
Coronation Asset Management (Pty) 3.98 3.98
Ltd
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional information
Place of completion Cape Town, South Africa
Date of completion 14/12/2018
Mediclinic has a primary listing on the Main Market of the LSE in the United Kingdom, with secondary listings on the
JSE in South Africa and the NSX in Namibia.
For further information, please contact:
Company Secretary, Link Company Matters Limited
Jayne Meacham / Caroline Emmet
+44 (0)20 7954 9569
Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181
Media queries
FTI Consulting
Brett Pollard/Debbie Scott – UK
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000
Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor: Simonis Storm Securities (Pty) Ltd
Date: 14/12/2018 03:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.